Page, R.L., Pritchett, E.L., Connolly, S., Wilkinson, W.E., For the SVA-4 Investigators (2008) Azimilide for the treatment of atrial fibrillation, atrial flutter, and paro- xysmal supraventricular tachycardia: Results of a ran-domized trial and insights on the concordance of symptoms and recurrent arrhythmias. Journal of Cardiovascular Electrophysiology, 19, 172-177. doi:10.1111/j.1540-8167.2007.00985.x

has been cited by the following article:

• TITLE: Novel therapies for treating atrial fibrillation

  AUTHORS: Raj Parikh, Philip J. Kadowitz

  KEYWORDS: Atrial Fibrillation; Atrial Flutter; Arrhythmia;Anticoagulation; Stroke

  JOURNAL NAME: World Journal of Cardiovascular Diseases, Vol.2 No.4, October 30, 2012

  ABSTRACT: Atrial fibrillation is the most common cardiac arrhythmia and is a major risk factor for stroke, heart failure, and death. Current treatments focus on anti-coagulation as well as rate-control and rhythm-control strategies. Frequent INR checks associated with warfarin along with several adverse side effects of anti-arrhythmics have propelled investigations into novel treatments for atrial fibrillation. Research is focused not only on pioneering new pharmacological antico- agulation and anti-arrhythmic agents but also on improving surgical techniques in hopes of treating the arrhythmia. Here, we first briefly discuss the current treatment options, both pharmacological and non-pharmacological, for atrial fibrillation. We then present a focused review of recent animal and human investigations that examine the use of novel an-ticoagulation agents, mechanisms of new anti-arrhythmics, analyze potential triggers of atrial fibrillation, and highlight the role of genetics in atrial fibrillation.